Antibody-drug conjugates get called biological missiles for a reason. The antibody finds the tumor cell, the payload kills it, and sitting between them is a small chemical structure that most people never think about until it fails. That structure is the ADC linker, and it decides whether the drug works safely or causes serious toxicity.
An ADC linker is the covalent connection between a monoclonal antibody and a cytotoxic small molecule. It sounds like a minor engineering detail, but the linker chemistry is often what separates a successful ADC program from one that gets shut down in early trials.
The Basic Problem Every Linker Has to Solve
A good linker has to behave two completely different ways depending on where it is.
While the ADC is circulating in the bloodstream, the linker needs to stay intact. If it breaks too early, the cytotoxic payload releases into healthy tissue instead of the tumor, and that’s how you get off-target toxicity — one of the most common reasons ADC candidates fail.
Once the ADC reaches the tumor cell and gets internalized, the linker needs to break apart quickly so the payload can do its job. Too slow, and the drug loses potency. Getting both properties into one small molecule is not simple, and it’s the reason linker design gets so much attention in ADC discovery programs.
Cleavable Linkers vs Non-Cleavable Linkers
This is the comparison most people are actually searching for, so here it is directly.
Cleavable linkers break down using conditions specific to the tumor environment or the inside of a cell.
- pH-sensitive linkers, like hydrazone-based ones, break apart in the acidic environment of the lysosome after the ADC gets internalized.
- Enzyme-cleavable linkers, most commonly Val-Cit (valine-citrulline), get cut by cathepsin B, an enzyme found at higher levels inside tumor cells. Val-Cit linkers are popular because they’re stable in blood plasma but cleave fast once inside the cell. Building the Val-Cit sequence itself depends on peptide coupling reagents, since it’s essentially a short peptide bond formation problem before it becomes a linker.
- Disulfide linkers rely on the higher glutathione concentration inside tumor cells compared to blood, which reduces the disulfide bond and releases the payload.
Non-cleavable linkers, like the MCC linker used in ado-trastuzumab emtansine, don’t rely on any triggered breakdown. Instead, the entire antibody gets degraded inside the lysosome by proteases, and the payload comes out still attached to an amino acid residue from the linker. This tends to give better plasma stability and a cleaner toxicity profile, though the released metabolite is a slightly different molecule than the original payload.
Neither type is universally “better” — the choice depends on the payload, the target antigen, and how much bystander effect the program wants.
PEG Chains in ADC Linker Design
Many of the payloads used in ADCs, such as MMAE or DXd, are highly hydrophobic. Attach several of these to one antibody and the whole conjugate can start aggregating in solution, which is a real problem for formulation and for dosing.
This is where PEG comes in. Adding a short polyethylene glycol segment into the linker structure improves water solubility, reduces aggregation, and can extend circulation half-life. Choosing the right PEG chain length is now a standard part of linker optimization, not an afterthought.
What Makes ADC Linker Synthesis Difficult
On paper, an ADC linker looks like a modest-sized molecule. In practice, it’s one of the harder synthetic targets in medicinal chemistry.
Most linkers have several reactive functional groups packed into one structure — a maleimide group for conjugation to the antibody’s cysteine residues, a peptide segment for enzymatic cleavage, sometimes a self-immolative spacer like PAB, and a PEG segment for solubility. Getting all of these to survive the same synthesis route without side reactions takes careful process design.
Stereochemistry adds another layer. Many linkers contain multiple chiral centers, and even small amounts of the wrong stereoisomer can change how the molecule behaves biologically. Holding tight enantiomeric excess across a multi-step synthesis is genuinely hard, especially once the molecule gets past ten or so steps.
Impurity control matters just as much. A trace side product that would be harmless in a simple intermediate can become a safety issue in a linker destined for a clinical ADC. The same rigor applied to controlling nitrosamine impurities in other drug intermediates applies here — small residual amounts are not acceptable once the molecule ends up in a conjugated biologic.
Why This Work Usually Goes to a Specialized CDMO
A full ADC linker synthesis, from starting materials to a maleimide-functionalized, PEGylated, peptide-containing final structure, can run fifteen to twenty steps or more. That’s well outside what a standard fine chemical manufacturer handles day to day, and it’s part of why the distinction between a CDMO and a CMO matters so much in this space — process development and analytical support are just as important as the manufacturing itself.
Arbor Pharmchem works in this exact niche. Our chemists handle complex multi-step organic synthesis, peptide coupling for sequences like Val-Cit, and PEG derivative chemistry as routine parts of the job. That covers standard linkers such as MC-Val-Cit-PAB at gram to hundred-gram scale, as well as custom process development for entirely new linker structures moving toward scale-up.
Frequently Asked Questions
What is the difference between cleavable and non-cleavable ADC linkers?
Cleavable linkers break down inside the tumor cell through pH changes, enzymes, or glutathione levels. Non-cleavable linkers stay attached until the whole antibody is degraded, releasing the payload with a linker fragment still attached.
Why is Val-Cit used so often as an ADC linker?
It stays stable in the bloodstream but gets cleaved quickly by cathepsin B once the ADC is inside a tumor cell, giving a good balance between safety and potency.
If your team is working through linker design or needs a synthesis partner for a complex ADC intermediate, reach out to Arbor Pharmchem to walk through a technical evaluation and quote for custom linker work.
